Keros Therapeutics Inc · Q2 2024 earnings

Briefing

Reported a net loss due to increased research and development efforts and additional investments to support clinical and corporate goals.

Keros Therapeutics reported a net loss of $45.3 million for the second quarter of 2024, compared to a net loss of $37.5 million for the same period in 2023. The increase in net loss was primarily due to increased research and development expenses.

• Keros continued to build upon the progress of all programs across its pipeline in the second quarter of 2024.
• Positive regulatory and data updates were received from the elritercept (KER-050) program.
• Strong enrollment activity has been observed in the Phase 2 clinical trial of cibotercept (KER-012) in patients with pulmonary arterial hypertension.
• Enrollment of the Phase 2 clinical trial of cibotercept (KER-012) is expected to be completed in the fourth quarter of this year.

Headline financials

Revenue & EPS history

Keros expects that the cash and cash equivalents it had on hand at June 30, 2024 will enable Keros to fund its operating expenses and capital expenditure requirements into 2027.